Skip to main content
. Author manuscript; available in PMC: 2013 Feb 7.
Published in final edited form as: Breast Cancer Res Treat. 2012 Jun 16;135(1):115–124. doi: 10.1007/s10549-012-2125-2

Fig. 6.

Fig. 6

Performance characteristics of nuclear nano-morphology markers described by cross-validated ROC curves to distinguish “malignant-adjacent” normal (Category 5) from normal (Category 1) and non-cancerous lesions (Categories 1–4). The discriminatory accuracy was assessed by the area under the ROC curve (AUROC)